Parabilis Medicines News and Activities
Presence
Headquarters: United States (USA)
Acquisition, funding and merger involving Parabilis Medicines.
- Parabilis Medicines has filed its IPO. Its stock ticker will be PBLS. (posted on May 20 2026).
- Parabilis Medicines has just announced a $305 Million fundraising (posted on January 8 2026).
Executives
View the org chart displaying its 38 main executives
Most searched biographies at Parabilis Medicines
- Mathai Mammen, Chairman of the Board, President and Chief Executiv...
- Alan Sebulsky, Director
- Edward Fitzgerald, Director
Popular executive movements at Parabilis Medicines
- Mark Ator, Associate Vice President, Discovery Drug Metabolism and Pharmacokinetics, has left the company (posted on May 20 2026).
- Brandon Allgood, Chief Data Science Officer, has left the company (posted on May 20 2026).
- Alan Sebulsky has joined the company as Director (posted on May 8 2026).
Click here to view some more movements at Parabilis Medicines
Create your alert
to follow the executive moves at Parabilis Medicines.
Pharmaceuticals
Parabilis Medicines has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).
Popular M&A news in Pharmaceuticals
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (posted on June 4 2026).
- Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
- Hims & Hers has acquired Eucalyptus (posted on June 2 2026).
Popular contacts in Pharmaceuticals
News
Press releases by Parabilis Medicines
- Parabilis Medicines Announces Strategic Collaboration with Regeneron Pharmaceuticals to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas - Parabilis Medicines
- Parabilis Medicines Announces Strategic Collaboration with Regeneron Pharmaceuticals to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas - Parabilis Medicines
- Parabilis Medicines Appoints Biopharmaceutical Finance Leader Alan M. Sebulsky to Board of Directors - Parabilis Medicines
- Parabilis Medicines Expands Executive Leadership Team - Parabilis Medicines
- Parabilis Medicines’ Zolucatetide, the First and Only Direct Inhibitor of the Elusive β-catenin:TCF Interaction, Receives FDA Orphan Drug Designation for the Treatment of Desmoid Tumors - Parabilis Medicines
- Parabilis Medicines Reports Early Clinical Evidence that Zolucatetide Reduces Polyp Burden in a Patient with Familial Adenomatous Polyposis - Parabilis Medicines
- Parabilis Medicines Announces Oversubscribed $305 Million Financing to Support Ongoing FOG-001 (zolucatetide) Clinical Development Across a Broad Range of Tumors and Advance Pioneering Pipeline and Helicon Platform - Parabilis Medicines
- Parabilis Medicines Highlights Promising Preliminary Clinical Results in Patients with Adamantinomatous Craniopharyngioma from Ongoing FOG-001 Clinical Trial at SNO 2025 - Parabilis Medicines
- Parabilis Medicines Receives FDA Fast Track Designation for FOG-001, the First and Only Direct Inhibitor of the β-catenin:TCF Interaction, for the Treatment of Desmoid Tumors - Parabilis Medicines
- Parabilis Medicines Presents Clinical and Preclinical Data Demonstrating Broad Potential of Helicon™ Peptides at AACR-NCI-EORTC 2025 - Parabilis Medicines
- View more press releases Close
Social media about Parabilis Medicines
- Parabilis Medicines on Wikipedia, Google News & Yahoo Finance
- Parabilis Medicines on LinkedIn, X (Twitter) & YouTube
